Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Eberjey Pink Ole Ole Halter Cami & French Brief
Popular Articles
Teeth Whitening Products

UGA Grad Program Expands To Prepare Teachers To Work With Secondary Students With Autism
An innovative University of Georgia graduate program in special education that has prepared scores of Georgia teachers to work with elementary-age students with autism over the last several years has received a new 4-year, $793,000 federal grant to train teachers to work with similarly challenged secondary-age students.
generic viagra online
News From The American Journal Of Pathology, August 2009
Topical Treatment Improves Wound Healing
News of the day
Ardea Biosciences Initiates Phase 2b Clinical Trial Of RDEA594, Lead Product Candidate For The Treatment Of Gout
Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced that it has initiated a Phase 2b clinical trial of RDEA594, its lead product candidate in development for the management of hyperuricemia and gout. The Company also announced the selection of RDEA684, a next-generation URAT1 inhibitor, as a development candidate for the same indication.
Public Health

Breakthrough Breast Cancer's Comment On New Targeted Antibody Therapy For Advanced Her2-Positive Breast Cancer

Dr Alexis Willett, Head of Policy & Involvement at Breakthrough Breast Cancer, says: "This study suggests that patients with HER2 positive advanced breast cancer who are no longer responding to Herceptin or chemotherapy may benefit from the combined Herceptin and DM1 treatment. Whilst many patients responded to the treatment in this trial, further larger studies will be needed to assess the full benefits. "There are limited treatments available for those with advanced breast cancer so improving the range of options is always welcome and we look forward to the results of the ongoing trials of this treatment." Breakthrough Breast Cancer


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009